By HANA KAHLEOVA
Tuesday is World Osteoporosis Day, and one number deserves more attention than it gets: one in two women over 50 will break a bone because of osteoporosis. Bone loss speeds up as estrogen falls during menopause. Yet in the rush to treat midlife weight gain with the newest drugs, bones rarely come up.
I think of a patient who sat down and named the drug before she said anything else. She was in her early 50s, and she wanted a GLP-1, the weekly injection everyone seems to be on now. She had gained weight around her middle that nothing would touch, and she had not slept through the night in months. Two or three times a night she woke up soaked, kicked off the covers and lay awake. Two of her friends had started the drug that spring. She expected a prescription, not a conversation.
She is a composite of women I have treated, but her request is common. About one in five adults ages 50 to 64 have taken a GLP-1 drug, the highest share of any age group. Many are women looking for relief from the weight gain and broken sleep of the menopause transition.
They have good reason to want something that works. For generations, women’s menopause symptoms were minimized or left for them to endure. A drug that finally does something can feel like overdue respect. In a 15-minute visit, it is also the fastest thing a doctor can offer. That is not an unreasonable choice. The question is whether it should be the first one.
What changed my answer for this patient was a line already in her chart. A bone density scan the year before had shown osteopenia, the thinning that comes before osteoporosis. It had earned a note to keep an eye on it and then dropped out of the conversation, as these findings so often do.
Here is why it mattered. The weight people lose on GLP-1 drugs is not all fat. Across clinical trials of these medications, roughly a quarter of the weight lost was lean mass. In one retrospective study of patients taking semaglutide or tirzepatide, bone density at the hip fell by nearly 3% over about three years. For a woman already losing bone as estrogen declines, rapid weight loss lands on top of an existing deficit. And about half of patients stop semaglutide within a year, often regaining weight, so some pay that cost without keeping the benefit.
So I asked her a simple question: Of everything bothering you, what is the worst part? It was not the weight. It was the nights. She had stopped making morning plans because she never knew what kind of night she would have.
That answer gave me something better to offer. In a randomized trial my colleagues and I published in the journal Menopause, 84 postmenopausal women with frequent hot flashes either switched to a low-fat, plant-based diet with half a cup of cooked soybeans a day or made no changes. After 12 weeks, moderate-to-severe hot flashes fell 88% in the diet group, compared with 34% in the control group. Half the women who changed their diet had no moderate-to-severe hot flashes left at all. Many also lost weight without counting calories.
I told her all of it, including the caveat that results vary and the only way to know is to try. I suggested 10 weeks, with the GLP-1 still on the table if nothing changed. She was skeptical. She had tried eating better before. I explained that this was not vague advice. It was a specific swap: less meat and dairy, more beans and lentils, and a daily serving of soybeans, tofu or soy milk, backed by a trial that measured exactly the symptom she wanted fixed.
She came back at 10 weeks. The night sweats had not vanished, but they had gone from most nights to about twice a week, and they were mild enough that she usually fell back asleep within minutes. She had lost a little weight. She had started making weekend plans again.
GLP-1 drugs are a real advance, and I prescribe them. For many women, they are the right choice. But our health care system is built to make the prescription the default. Short visits reward it. Insurers pay for it more readily than for the time it takes to explore other options. Bone density results get filed and forgotten. None of that serves women in midlife well.
Women can push back. Before starting any weight-loss drug, ask what your last bone density scan showed, or whether you need one. Ask what else could address the symptom that bothers you most. Doctors can start by asking what is actually driving the visit. And insurers should cover nutrition counseling and follow-up as readily as they cover the drug, so the choice is real.
Now, when a patient asks me for a GLP-1, I ask first what is keeping her up at night. Women in midlife have waited long enough to be asked.
Hana Kahleova, MD, PhD, is a physician board-certified in internal medicine, endocrinology and lifestyle medicine, and director of clinical research at the Physicians Committee for Responsible Medicine, a nonprofit that advocates plant-based nutrition and funded the hot flash trial described here. The patient described is a composite drawn from her clinical experience.
